Scientific Presentations

Scientific Presentations

All Publications

Date	Focus	Title of Publication
March 2021	Preclinical	Mast Cell and Eosinophil Activation Are Associated With COVID-19 and TLR-Mediated Viral Inflammation: Implications for an Anti-Siglec-8 Antibody Front. Immunol.
January 2021	Clinical	Diagnostic Delay in Patients with Eosinophilic Gastritis and/or Duodenitis: A Population-Based Study The Journal of Allergy and Clinical Immunology: In Practice
November 2020	Preclinical	Discovery, Function, and Therapeutic Targeting of Siglec-8 Cells
October 2020	Clinical	Anti–Siglec-8 Antibody for Eosinophilic Gastritis and Duodenitis New England Journal of Medicine
June 2020	Preclinical	An anti‐siglec‐8 antibody depletes sputum eosinophils from asthmatic subjects and inhibits lung mast cells Clinical & Experimental Allergy
August 2020	Preclinical	A monoclonal antibody to Siglec-8 suppresses non-allergic airway inflammation and inhibits IgE-independent mast cell activation Mucosal Immunology
June 2020	Preclinical	An anti‐siglec‐8 antibody depletes sputum eosinophils from asthmatic subjects and inhibits lung mast cells Clinical & Experimental Allergy
June 2020	Clinical	Treatment of Severe Allergic Conjunctivitis with AK002 Indicated Improvement of Ocular Signs and Symptoms and Reduction of Severity of Comorbid Atopic Diseases in a Phase 1b Open-Label Study European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting
June 2020	Preclinical	A Siglec-8 Antibody Reduces Substance P-induced Inflammation by Inhibiting MRGPR-mediated Mast Cell Activation European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting
May 2020	Clinical	Interim Results of an Open-label Extension Study of Antolimab, an Anti-Siglec-8 Antibody, for the Treatment of Patients with Eosinophilic Gastritis and/or Eosinophilic Duodenitis Digestive Disease Week (DDW) Annual Meeting
May 2020	Clinical	Primary Results of A Phase 1 Multicenter Open- Label Study of Antolimab, An Anti-Siglec-8 Antibody, for the Treatment of Patients With Chronic Gastrointestinal Symptoms and Elevated Gastric and/or Duodenal Mast Cells Digestive Disease Week (DDW) Annual Meeting
May 2020	Disease State	Mast Cells Are Significantly Activated In Patients with Ulcerative Colitis and Are Inhibited by an Anti-Siglec-8 Antibody, Antolimab (AK002) Digestive Disease Week (DDW) Annual Meeting
May 2020	Disease State	EGID Biopsies Have Functionally Distinct and Activated Mast Cells That Contribute to Disease Pathogenesis and Are Inhibited By an Anti-Siglec-8 Antibody, Antolimab (AK002) Digestive Disease Week (DDW) Annual Meeting
May 2020	Clinical	Histologic and Symptomatic Improvement Across Multiple Forms of Eosinophilic Gastrointestinal Diseases in ENIGMA, a Randomized, Double-Blind, Placebo-Controlled Trial of Antolimab (AK002) Digestive Disease Week (DDW) Annual Meeting
March 2020	Clinical	AK002, an Anti-Siglec-8 Antibody, Depletes Tissue Eosinophils and Improves Dysphagia Symptoms in Patients with Eosinophilic Esophagitis (pdf) American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting
March 2020	Clinical	Clinical Activity of AK002, an Anti-Siglec-8 Monoclonal Antibody, in Treatment-Refractory Chronic Urticaria (pdf) American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting
March 2020	Preclinical	AK002, an Anti-Siglec-8 Antibody, Suppresses Acute IL-33-induced Neutrophil Infiltration and Attenuates Tissue Damage in a Chronic Experimental COPD Model Through Mast Cell Inhibition (#568) (pdf) American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting
March 2020	Clinical	Phase 1b Study of AK002, an Anti-Siglec-8 Monoclonal Antibody, in Patients with Severe Allergic Conjunctivitis (KRONOS Study) (pdf) American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting
March 2020	Preclinical	Atopic Dermatitis Skin Biopsies Have High Numbers of Activated Mast Cells that are Inhibited by AK002 after Stimulation Ex Vivo (pdf) American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting
March 2020	Disease State	EoE Biopsies have Elevated and Activated Mast Cells that Produce Cytokines and Chemokines that Drive Disease Pathogenesis (pdf) American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting
March 2020	Disease State	A Longitudinal, Population-Based Study of the Difficult Journey to Diagnosis Endured by Patients with Eosinophilic Gastritis and Eosinophilic Gastroenteritis (pdf) American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting
January 2020	Preclinical	Antolimab (AK002), an Anti-Siglec-8 Antibody, Inhibits IL-33-mediated Mast Cell Activation and Neutrophilic Inflammation (pdf) Gordon Research Conference on Food Allergy in the Context of Mucosal Homeostasis and Immunity
January 2020	Disease State	Phenotypic Characterization of Inflammatory Bowel Disease Biopsies Reveal That Mast Cells Are Significantly Elevated and Activated In Patients with Ulcerative Colitis (pdf) Crohn’s & Colitis Congress
November 2019	Disease State	Time to Diagnosis of Eosinophilic Gastritis and Eosinophilic Enteritis Improves When Patients Are Co-Managed by an Allergist and Gastroenterologist (pdf) American College of Allergy, Asthma & Immunology (ACAAI) Annual Meeting
October 2019	Clinical	Symptomatic Patients Suspected of Eosinophilic Gastritis and/or Gastroenteritis Have Elevated Mucosal Mast Cell Counts Without Eosinophilia (pdf) American College of Gastroenterology (ACG) Annual Meeting
October 2019	Disease State	Additional Support Needed for Successful Transition of Care from Pediatric to Adult Providers for the Management of Eosinophilic Gastrointestinal Diseases (pdf) American College of Gastroenterology (ACG) Annual Meeting
October 2019	Disease State	Eosinophilic Gastritis and Eosinophilic Enteritis Patients Endure a Lengthy Path to Diagnosis and Experience Persistent Symptoms After Diagnosis (pdf) American College of Gastroenterology (ACG) Annual Meeting
October 2019	Clinical	Efficacy and Safety of AK002 in Adult Patients with Active Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis: Primary Results from a Randomized, Double-Blind Placebo-Controlled Phase 2 Trial (ENIGMA Study) (pdf) American College of Gastroenterology (ACG) Annual Meeting
August 2019	Preclinical	AK002, a Humanized Sialic Acid-Binding Immunoglobulin-Like Lectin-8 Antibody that Induces Antibody-Dependent Cell-Mediated Cytotoxicity against Human Eosinophils and Inhibits Mast Cell-Mediated Anaphylaxis in Mice International Archives of Allergy and Immunology
August 2019	Preclinical	Siglec-8 antibody reduces eosinophil and mast cell infiltration in a transgenic mouse model of eosinophilic gastroenteritis JCI Insight
June 2019	Preclinical	Inhibition of Mast Cells with a Siglec-8 Antibody Reduces Tissue Damage in Models of Skin and Lung Fibrosis and COPD European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting
June 2019	Preclinical	Eosinophilic Esophagitis and Gastritis Patient Biopsies Have High Levels of Activated Eosinophils and Mast Cells That Are Inhibited by AK002 (pdf) European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting
June 2019	Clinical	Efficacy and Safety Data of AK002, an Anti-Siglec-8 Monoclonal Antibody, in Patients with Multiple Forms of Uncontrolled Chronic Urticaria (CU): Results from an Open-label Phase 2a Study (pdf) European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting
June 2019	Clinical	Safety and Efficacy Data of AK002, an Anti-Siglec-8 Monoclonal Antibody, in Patients with Indolent Systemic Mastocytosis (ISM): Results from a First-in-Human, Open-label Phase 1 Study (pdf) European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting
June 2019	Disease State	The Tortuous Path to Diagnosis of Eosinophilic Gastritis and Eosinophilic Gastroenteritis (EG/EGE) in the United States: A Real-World, Population-Based Study (pdf) European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting
May 2019	Disease State	Mast Cells in Addition to Eosinophils Are Markedly Elevated in Patients with Eosinophilic Gastritis and/or Gastroenteritis (pdf) Digestive Disease Week (DDW) Annual Meeting
November 2018	Preclinical	AK002, a Novel Siglec-8 Antibody Depletes Human Eosinophils and Inhibits Anaphylaxis in Humanized Mice American College of Allergy, Asthma & Immunology (ACAAI) Annual Meeting
March 2018	Clinical	Phase 1 Double-Blind, Placebo-Controlled, Ascending Dose Study of Siglec-8 Selective mAb AK002 in Healthy Subjects American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting

Clinical

Date	Focus	Title of Publication
January 2021	Clinical	Diagnostic Delay in Patients with Eosinophilic Gastritis and/or Duodenitis: A Population-Based Study The Journal of Allergy and Clinical Immunology: In Practice
October 2020	Clinical	Anti–Siglec-8 Antibody for Eosinophilic Gastritis and Duodenitis New England Journal of Medicine
June 2020	Preclinical	An anti‐siglec‐8 antibody depletes sputum eosinophils from asthmatic subjects and inhibits lung mast cells Clinical & Experimental Allergy
June 2020	Clinical	Treatment of Severe Allergic Conjunctivitis with AK002 Indicated Improvement of Ocular Signs and Symptoms and Reduction of Severity of Comorbid Atopic Diseases in a Phase 1b Open-Label Study European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting
May 2020	Clinical	Interim Results of an Open-label Extension Study of Antolimab, an Anti-Siglec-8 Antibody, for the Treatment of Patients with Eosinophilic Gastritis and/or Eosinophilic Duodenitis Digestive Disease Week (DDW) Annual Meeting
May 2020	Clinical	Primary Results of A Phase 1 Multicenter Open- Label Study of Antolimab, An Anti-Siglec-8 Antibody, for the Treatment of Patients With Chronic Gastrointestinal Symptoms and Elevated Gastric and/or Duodenal Mast Cells Digestive Disease Week (DDW) Annual Meeting
May 2020	Clinical	Histologic and Symptomatic Improvement Across Multiple Forms of Eosinophilic Gastrointestinal Diseases in ENIGMA, a Randomized, Double-Blind, Placebo-Controlled Trial of Antolimab (AK002) Digestive Disease Week (DDW) Annual Meeting
March 2020	Clinical	AK002, an Anti-Siglec-8 Antibody, Depletes Tissue Eosinophils and Improves Dysphagia Symptoms in Patients with Eosinophilic Esophagitis (pdf) American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting
March 2020	Clinical	Clinical Activity of AK002, an Anti-Siglec-8 Monoclonal Antibody, in Treatment-Refractory Chronic Urticaria (pdf) American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting
March 2020	Clinical	Phase 1b Study of AK002, an Anti-Siglec-8 Monoclonal Antibody, in Patients with Severe Allergic Conjunctivitis (KRONOS Study) (pdf) American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting
October 2019	Clinical	Symptomatic Patients Suspected of Eosinophilic Gastritis and/or Gastroenteritis Have Elevated Mucosal Mast Cell Counts Without Eosinophilia (pdf) American College of Gastroenterology (ACG) Annual Meeting
October 2019	Clinical	Efficacy and Safety of AK002 in Adult Patients with Active Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis: Primary Results from a Randomized, Double-Blind Placebo-Controlled Phase 2 Trial (ENIGMA Study) (pdf) American College of Gastroenterology (ACG) Annual Meeting
June 2019	Clinical	Efficacy and Safety Data of AK002, an Anti-Siglec-8 Monoclonal Antibody, in Patients with Multiple Forms of Uncontrolled Chronic Urticaria (CU): Results from an Open-label Phase 2a Study (pdf) European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting
June 2019	Clinical	Safety and Efficacy Data of AK002, an Anti-Siglec-8 Monoclonal Antibody, in Patients with Indolent Systemic Mastocytosis (ISM): Results from a First-in-Human, Open-label Phase 1 Study (pdf) European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting
March 2018	Clinical	Phase 1 Double-Blind, Placebo-Controlled, Ascending Dose Study of Siglec-8 Selective mAb AK002 in Healthy Subjects American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting

Preclinical

Date	Focus	Title of Publication
March 2021	Preclinical	Mast Cell and Eosinophil Activation Are Associated With COVID-19 and TLR-Mediated Viral Inflammation: Implications for an Anti-Siglec-8 Antibody Front. Immunol.
November 2020	Preclinical	Discovery, Function, and Therapeutic Targeting of Siglec-8 Cells
August 2020	Preclinical	A monoclonal antibody to Siglec-8 suppresses non-allergic airway inflammation and inhibits IgE-independent mast cell activation Mucosal Immunology
June 2020	Preclinical	An anti‐siglec‐8 antibody depletes sputum eosinophils from asthmatic subjects and inhibits lung mast cells Clinical & Experimental Allergy
June 2020	Preclinical	A Siglec-8 Antibody Reduces Substance P-induced Inflammation by Inhibiting MRGPR-mediated Mast Cell Activation European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting
March 2020	Preclinical	AK002, an Anti-Siglec-8 Antibody, Suppresses Acute IL-33-induced Neutrophil Infiltration and Attenuates Tissue Damage in a Chronic Experimental COPD Model Through Mast Cell Inhibition (#568) (pdf) American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting
March 2020	Preclinical	Atopic Dermatitis Skin Biopsies Have High Numbers of Activated Mast Cells that are Inhibited by AK002 after Stimulation Ex Vivo (pdf) American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting
January 2020	Preclinical	Antolimab (AK002), an Anti-Siglec-8 Antibody, Inhibits IL-33-mediated Mast Cell Activation and Neutrophilic Inflammation (pdf) Gordon Research Conference on Food Allergy in the Context of Mucosal Homeostasis and Immunity
August 2019	Preclinical	AK002, a Humanized Sialic Acid-Binding Immunoglobulin-Like Lectin-8 Antibody that Induces Antibody-Dependent Cell-Mediated Cytotoxicity against Human Eosinophils and Inhibits Mast Cell-Mediated Anaphylaxis in Mice International Archives of Allergy and Immunology
August 2019	Preclinical	Siglec-8 antibody reduces eosinophil and mast cell infiltration in a transgenic mouse model of eosinophilic gastroenteritis JCI Insight
June 2019	Preclinical	Inhibition of Mast Cells with a Siglec-8 Antibody Reduces Tissue Damage in Models of Skin and Lung Fibrosis and COPD European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting
June 2019	Preclinical	Eosinophilic Esophagitis and Gastritis Patient Biopsies Have High Levels of Activated Eosinophils and Mast Cells That Are Inhibited by AK002 (pdf) European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting
November 2018	Preclinical	AK002, a Novel Siglec-8 Antibody Depletes Human Eosinophils and Inhibits Anaphylaxis in Humanized Mice American College of Allergy, Asthma & Immunology (ACAAI) Annual Meeting

Disease State

Date	Focus	Title of Publication
May 2020	Disease State	Mast Cells Are Significantly Activated In Patients with Ulcerative Colitis and Are Inhibited by an Anti-Siglec-8 Antibody, Antolimab (AK002) Digestive Disease Week (DDW) Annual Meeting
May 2020	Disease State	EGID Biopsies Have Functionally Distinct and Activated Mast Cells That Contribute to Disease Pathogenesis and Are Inhibited By an Anti-Siglec-8 Antibody, Antolimab (AK002) Digestive Disease Week (DDW) Annual Meeting
March 2020	Disease State	EoE Biopsies have Elevated and Activated Mast Cells that Produce Cytokines and Chemokines that Drive Disease Pathogenesis (pdf) American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting
March 2020	Disease State	A Longitudinal, Population-Based Study of the Difficult Journey to Diagnosis Endured by Patients with Eosinophilic Gastritis and Eosinophilic Gastroenteritis (pdf) American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting
January 2020	Disease State	Phenotypic Characterization of Inflammatory Bowel Disease Biopsies Reveal That Mast Cells Are Significantly Elevated and Activated In Patients with Ulcerative Colitis (pdf) Crohn’s & Colitis Congress
November 2019	Disease State	Time to Diagnosis of Eosinophilic Gastritis and Eosinophilic Enteritis Improves When Patients Are Co-Managed by an Allergist and Gastroenterologist (pdf) American College of Allergy, Asthma & Immunology (ACAAI) Annual Meeting
October 2019	Disease State	Additional Support Needed for Successful Transition of Care from Pediatric to Adult Providers for the Management of Eosinophilic Gastrointestinal Diseases (pdf) American College of Gastroenterology (ACG) Annual Meeting
October 2019	Disease State	Eosinophilic Gastritis and Eosinophilic Enteritis Patients Endure a Lengthy Path to Diagnosis and Experience Persistent Symptoms After Diagnosis (pdf) American College of Gastroenterology (ACG) Annual Meeting
June 2019	Disease State	The Tortuous Path to Diagnosis of Eosinophilic Gastritis and Eosinophilic Gastroenteritis (EG/EGE) in the United States: A Real-World, Population-Based Study (pdf) European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting
May 2019	Disease State	Mast Cells in Addition to Eosinophils Are Markedly Elevated in Patients with Eosinophilic Gastritis and/or Gastroenteritis (pdf) Digestive Disease Week (DDW) Annual Meeting